Seaport Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series B

Recent Raise

$225M

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.